{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:35:55Z","timestamp":1791639355131,"version":"4.3.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004085","name":"Ministry of Education, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004085","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.diagmicrobio.2012.01.015","type":"journal-article","created":{"date-parts":[[2012,5,22]],"date-time":"2012-05-22T15:28:56Z","timestamp":1337700536000},"page":"264-266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["In vitro activities of ceftobiprole, dalbavancin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus blood isolates: stratified analysis by vancomycin MIC"],"prefix":"10.1016","volume":"73","author":[{"given":"Yong Pil","family":"Chong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Jin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Sueng","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Sil","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi-Na","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Han","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Oh","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Ho","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Yong","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Hee","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2012.01.015_bb0005","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.diagmicrobio.2008.10.011","article-title":"Application of patient population-derived pharmacokinetic\u2013pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci","volume":"63","author":"Ambrose","year":"2009","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2012.01.015_bb0010","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2165\/11317100-000000000-00000","article-title":"Clinical pharmacokinetics and pharmacodynamics of tigecycline","volume":"48","author":"Barbour","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.diagmicrobio.2012.01.015_bb0015","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1128\/JCM.02368-06","article-title":"Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States","volume":"45","author":"Biedenbach","year":"2007","journal-title":"J.\u00a0Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2012.01.015_bb0020","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, M7-A8","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2009"},{"issue":"Suppl 5","key":"10.1016\/j.diagmicrobio.2012.01.015_bb0025","doi-asserted-by":"crossref","first-page":"S386","DOI":"10.1086\/533595","article-title":"Management of methicillin-resistant Staphylococcus aureus bacteremia","volume":"46","author":"Cosgrove","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2012.01.015_bb0030","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1128\/AAC.50.3.1079-1082.2006","article-title":"Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus","volume":"50","author":"Cui","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2012.01.015_bb0035","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1086\/648720","article-title":"Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials","volume":"50","author":"Gardiner","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2012.01.015_bb0040","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijantimicag.2010.10.030","article-title":"Management of serious meticillin-resistant Staphylococcus aureus infections: what are the limits?","volume":"37","author":"Gould","year":"2011","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diagmicrobio.2012.01.015_bb0045","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1469-0691.2007.01888.x","article-title":"Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan","volume":"14","author":"Huang","year":"2008","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.diagmicrobio.2012.01.015_bb0050","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.diagmicrobio.2010.08.006","article-title":"Correlation between vancomycin and daptomycin MIC values for methicillin-susceptible and methicillin-resistant Staphylococcus aureus by 3 testing methodologies","volume":"68","author":"Keel","year":"2010","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2012.01.015_bb0055","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1128\/AAC.00113-08","article-title":"Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin.","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl 5","key":"10.1016\/j.diagmicrobio.2012.01.015_bb0060","doi-asserted-by":"crossref","first-page":"S333","DOI":"10.1086\/431674","article-title":"The pharmacokinetic and pharmacodynamic profile of tigecycline","volume":"41","author":"Meagher","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2012.01.015_bb0065","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/cir764","article-title":"Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study","volume":"54","author":"Moore","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2012.01.015_bb0070","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1128\/AAC.48.5.1713-1718.2004","article-title":"Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141","volume":"48","author":"Mouton","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2012.01.015_bb0075","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1128\/AAC.00307-09","article-title":"Correlation between vancomycin MIC values and those of other agents against Gram-positive bacteria among patients with bloodstream infections caused by methicillin-resistant Staphylococcus aureus","volume":"53","author":"Patel","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2012.01.015_bb0080","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/jac\/dkr024","article-title":"Spread of methicillin-resistant Staphylococcus aureus between the community and the hospitals in Asian countries: an ANSORP study","volume":"66","author":"Song","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2012.01.015_bb0085","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1086\/524667","article-title":"Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"46","author":"Soriano","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2012.01.015_bb0090","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/jac\/dkm258","article-title":"Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001\u201305","volume":"60","author":"Steinkraus","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2012.01.015_bb0095","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1128\/AAC.00676-08","article-title":"Improved antimicrobial activity of linezolid against vancomycin-intermediate Staphylococcus aureus","volume":"52","author":"Watanabe","year":"2008","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889312000375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889312000375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:51:10Z","timestamp":1760003470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889312000375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0732889312000375"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2012.01.015","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activities of ceftobiprole, dalbavancin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus blood isolates: stratified analysis by vancomycin MIC","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2012.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}